Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805
Checked against the public recordLast updated Jun 30, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Revolution Medicines, Inc.
- Interventions being studied
- Drug: RMC-6291; Drug: RMC-6236; Drug: Pembrolizumab; Drug: Cisplatin; Drug: Carboplatin; Drug: Pemetrexed; Drug: RMC-9805
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion criteria: All Patients (unless otherwise noted): * ≥ 18 years of age * ECOG PS is 0 to 1 * Adequate organ function as outlined by the study * Received prior standard therapy appropriate for tumor type and stage * Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A) * Must have pathologically documented, locally advanced or metastatic RAS-mutated NSCLC (Subprotocol B) * Must have pathologically documented, locally advanced or metastatic RAS G12D-mutated NSCLC (Subprotocol C and Subprotocol D) Exclusion criteria: All Patients: * Primary central nervous system (CNS) tumors * Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs * Major surgery \< 28 days of first dose * Active or history of interstitial lung disease (ILD) or pneumonitis requiring steroids Other inclusion/exclusion criteria may apply.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Banner MD Anderson Cancer CenterGilbert, Arizona
- City of Hope - DuarteDuarte, California
- City of Hope - LennarIrvine, California
- UC Davis, Davis Comprehensive Cancer CenterSacramento, California
- University of California, San Diego Moores Cancer CenterSan Diego, California
- UCSF Medical Center - Mission BaySan Francisco, California
- Stanford University - Stanford Cancer InstituteStanford, California
- Colorado Health Medical Group - Medical Oncology & HematologyColorado Springs, Colorado
- Georgetown University Medical CenterWashington D.C., District of Columbia
- Boca Raton Clinical Research AssociatesPlantation, Florida
- Cancer Specialists of North FloridaSaint Augustine, Florida
- H Lee Moffitt Cancer Center and Research InstituteTampa, Florida
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 30, 2026. Always confirm current availability with the study team.